TREATMENT OF HEPATITIS C VIRUS IN UNDERSERVED POPULATIONS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。我们建议进行一项研究，以评估治疗丙型肝炎的药物使用者的可行性。我们假设，通过最大限度地利用促进剂和最大限度地减少治疗障碍，我们可以使药物使用者能够接受有效的丙型肝炎治疗。具体目标是：1.估计从社区现场地点转介给丙型肝炎治疗评估的药物使用的比例，这些药物使用者(A)完成丙型肝炎治疗的医学评估，(B)接受丙型肝炎的抗病毒治疗，以及(C)完成丙型肝炎的抗病毒治疗。2.描述与完成这些结果相关的药物使用者的特征。3.确定(即定性描述和量化)不开始治疗和停止治疗的原因。4.描述聚乙二醇化干扰素联合利巴韦林方案在吸毒者中的安全性和有效性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We propose to conduct a study to assess the feasibility of treating drug users for hepatitis C. We hypothesize that by maximizing facilitators and minimizing barriers to treatment we can enable drug users to receive effective treatment for hepatitis C. The specific aims are: 1. To estimate the proportions of drug uses referred from community-based field sites presenting for evaluation for hepatitis C treatment who (a) complete a medical evaluation for hepatitis C treatment, (b) receive antiviral treatment for hepatitis C, and (c) complete antiviral treatment for hepatitis C. 2. To describe the characteristics of drug users associated with completion of these outcomes. 3. To determine (i.e., describe qualitively and quantify) reasons for not starting treatment and for treatment discontinuation. 4. To describe the safety and efficacy of the pegylated interferon and ribavirin regimen in active drug users.